Extracorporeal Lung Assist Device in Acute Lung Impairment

Acute Respiratory Distress Syndrome Clinical Trial

— EXODUS  

Official title:

EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02550600
• Other study ID #: EXO_1
• Status: Not yet recruiting
• Phase: N/A
• First received: July 24, 2015
• Last updated: September 11, 2015
• Start date: November 2015
• Est. completion date: December 2017

Study information

• Verified date: September 2015
• Source: Technische Universität München
• Contact: Wolfgang Huber, MD
• Phone: ++49-89-4140-5214
• Email: Wolfgang.Huber[@]lrz.tum.de
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effect of interventional Lung Assist iLA activve to standard therapy in mechanically ventilated patients with severe acute lung impairment. Hypothesis: iLA(active) reduces the incidence of an increase in SOFA-Score of ≥3 points (or death) within 28 days compared to standard treatment.

Description:

Background:

Mechanical ventilation in patients with acute lung impairment further injures the lungs by inspiration forces and inflammatory response. Large efforts have been invested in reducing ventilator-associated lung damage by lower tidal volumes. However, benefits are limited by potential harms of permissive hypercapnia.

Therefore, extracorporeal membrane oxygenation (ECMO) and CO2-removal have been studied for more than 40 years. However, ECMO remained restricted to few specialized centres capable to provide extensive resources. Transfer of patients implicates loss of time and risks of transportation. Therefore, less invasive devices have been developed, including "pump-less "extracorporeal lung assist" (pECLA) and pump-driven ECLA (e.g. iLA activve). Despite pilot trials supporting feasibility, safety and efficient oxygenation and decarboxylation by pump-driven ECLA, there are no randomized controlled trials (RCT) proving a benefit regarding long-term endpoints.

Objectives:

Therefore, the aim of this multicentre RCT is to compare the outcome of 150 patients with early (after ≤96h of mechanical ventilation) acute lung impairment treated by pump-driven ECLA with iLA activve with a blood flow of at least 1L/min vs. 150 controls with standard intensive care including low tidal volume ventilation.

Main inclusion and exclusion criteria:

While most trials on ECMO and (p)ECLA included patients in a rescue scenario with severe and persisting ARDS, earlier inclusion also implicates modified inclusion criteria: A cumulative Murray score of ≥6 points without radiological points is the most important inclusion criterion. At least four points must result from pO2/FiO2 (mandatory pO2/FiO2<300mmHg) and PEEP criteria of the Murray score. In order to provide sufficient time for conservative attempts to optimize ventilation, inclusion criteria can be fulfilled for a maximum of 48h before inclusion as long as the patient can be included within a maximum of 96h of mechanical ventilation.

Primary efficacy endpoint:

Incidence of an increase in SOFA-Score ≥3 points or death within 28 days.

Statistical analyses:

Generalized linear mixed model (logit link function) will be used to compare the primary efficacy endpoint, the proportion of patients with an increase in SOFA of ≥3 points or death within 28d, between the two groups. In this analysis the random factor variable study centre and anticoagulation therapy will be considered as adjustment variables. The test of group effect estimated by the multivariable mixed logistic model will be conducted at a two-sided 0.05 level of significance.

The primary efficacy analysis will be based on the intention-to-treat population. Missing values of SOFA score will be replaced by last-value carry forward approach.

Survival status of lost to follow-up patients will be replaced conservatively: missing survival status will be replaced by attribute "death" for patients in the verum arm and replaced by attribute "alive" for patients in the standard treatment arm.

A supportive complete case and per-protocol analysis will be conducted for purpose of sensitivity analysis of the primary endpoint. Further sensitivity analyses will be provided to evaluate robustness of results in regard to unexpected circumstances (e.g. impact of 'cross-over' patients who are not treated as randomized but are required to be analyzed as randomized (ITT-principle)). Secondary endpoints will be analyzed in an exploratory manner.

Chi-Square test or Fisher-exact test will be used to compare categorical data. For comparisons of continuous data between groups non-parametric tests (Kruskal-Wallis test, Mann-Whitney-U test) will be performed. 95% confidence intervals will be calculated for relevant measurements. SAS software (version 4.9 or future follow-up version).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: December 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Potentially reversible lung failure AND

• Cumulative Murray score =6 points without radiological points for a maximum of 48h AND

• Cumulative Murray score =4 points for pO2/FiO and PEEP AND

• Cumulative Murray score =1 point for pO2/FiO

• Mechanical ventilation for =96h AND

• Age = 18 years.

Exclusion Criteria:

• SOFA-Score >20

• Life expectancy <24h

• mechanical ventilation >96h

• Heparin-induced thrombopenia

• Intracranial bleeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn

Intervention

Procedure:
• iLA activve treatment
iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of =2L/min. The length of therapy is at the discretion of the treating physician. Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2=65mmHg, P_peak =30cm H2O, TV =6ml/kg PBW and pH =7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg = pCO2 =45mmHg, Delta-pressure (= P_peak - PEEP) =15 cm H2O and P_peak =25 cm H2O. iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow).
• Control group
The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group. There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group.

Locations

Country	Name	City	State
Austria	Medical University of Vienna/General Hospital of Vienna	Vienna
Germany	Klinik für Intensivmedizin; Universitätsklinikum Hamburg-Eppendorf (UKE)	Hamburg
Germany	II. Medizinische Klinik; Klinikum rechts der Isar; Technische Universität München	München
Germany	Klinik für Anästhesiologie; Klinikum rechts der Isar; Technische Universität München	München
Germany	Abteilung für Intensivmedizin; Krankenhaus Barmherzige Brüder; München	Munich
Germany	I. Medizinische Klinik; Klinikum rechts der Isar; Technische Universität München	Munich
Hungary	Department of Anaesthesiology and Intensive Therapy; University of Szeged	Szeged
United Kingdom	St. Bartholomew's & London Chest Hospitals	London

Sponsors (3)

Lead Sponsor	Collaborator
Technische Universität München	Novalung GmbH, Heilbronn, Germany, Studiensekretariat Intensivmedizin; II. Medizinische Klinik; Klinikum rechts der Isar; Munich

Countries where clinical trial is conducted

Austria,  Germany,  Hungary,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of an increase in SOFA-Score =3 points or death within 28 days		28 days	No
Secondary	Death or severe disability after 6 months defined as confinement to bed and inability to wash or dress alone		6 months	Yes
Secondary	Mortality		28 days, 60 days, ICU-stay	Yes
Secondary	Ventilator free days		28 days, ICU stay	No
Secondary	Single organ failures as assessed by SOFA		28 days, ICU stay	No
Secondary	Prediction of outcome (Primary endpoint: Incidence of an increase in SOFA-Score =3 points or death within 28 days)	Uni- and multivariate analysis of the predictive capabilities of baseline values of extravascular lung water index and graduation of ARDS (AECC- and Berlin definition of ARDS, Murray-score)	28 days	No
Secondary	Safety analysis assessed by documentation of complications and side effects potentially related to iLA activve and/or conventional therapy including complications associated to cannulation and extracorporeal circuit,	thrombosis, pulmonary embolism, pneumothorax, use of tube thoracostomies	6 months	Yes
Secondary	Meta-analysis	Meta-analysis of this study and other high-quality RCTs on extracorporeal lung Support regarding survival to 6 months without disability, all cause mortality on day 60.	6 months	No
Secondary	Resource use and economic outcomes	Comparison of resource use based on DRG-calculation	6 months	No
Secondary	Early vs. late intervention	Comparison of outcome of patients with early iLA activve (Intervention group) to late iLA activve (Control group with cross-over): survival to 6 months without disability, mortality after 28 days, 60 days and 6 months.	6 months	Yes
Secondary	Prediction of outcome (Death or severe disability after 6 months defined as confinement to bed and inability to wash or dress alone)	Uni- and multivariate analysis of the predictive capabilities of baseline values of extravascular lung water index and graduation of ARDS (AECC- and Berlin definition of ARDS, Murray-score)	6 months	No
Secondary	Association of the fluid balance to the primary endpoint (Incidence of an increase in SOFA-Score =3 points or death within 28 days)	Uni- and multivariate analysis regarding the association of the cumulative fluid balance with the primary endpoint	28 days	No
Secondary	Association of the fluid balance to the secondary endpoint "death or severe disability after 6 months defined as confinement to bed and inability to wash or dress alone)"	Uni- and multivariate analysis regarding the association of the cumulative fluid balance with the secondary endpoint	6 months	No